Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment

被引：19

作者：

Du Pasquier-Fediaevsky, Laurence ^{[1
]}

Andrei, Stefan ^{[1
]}

Berche, Michel ^{[2
]}

Leenhardt, Laurence ^{[3
]}

Heron, Emmanuel ^{[1
]}

Riviere, Sebastien ^{[4
]}

机构：

[1] Ctr Hosp Natl Ophtalmol Quinze Vingts, Dept Internal Med, Paris 12, France

[2] Ctr Hosp Natl Ophtalmol Quinze Vingts, Dept Ophthalmol 4, Paris 12, France

[3] Ctr Hosp Univ Pitie Salpetriere, Inst E3M, Paris 13, France

[4] Ctr Hosp Univ St Antoine, Dept Internal Med, Paris 12, France

来源：

OCULAR IMMUNOLOGY AND INFLAMMATION | 2019年 / 27卷 / 05期

关键词：

Corticoresistant; Graves' orbitopathy; low-dose; rituximab; treatment; EFFICACY; OPHTHALMOPATHY; TRIAL; MANAGEMENT; THERAPY;

D O I：

10.1080/09273948.2018.1453078

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To report low-dose rituximab effect in Graves' orbitopathy (GO) resistant to conventional treatment. Methods: Retrospective analysis of medical records, filled in according to the European Group on Graves' Orbitopathy (EUGOGO) standards, of patients with active moderate-to-severe GO who received low-dose rituximab after failure of conventional treatment. Efficacy was defined by a decrease of the clinical activity score of 2 points or Results: Among 219 patients treated between 2012 and 2016 by pulse methylprednisolone, possibly followed by oral steroids and/or orbital radiotherapy, 15 (6.8%) finally received 100 mg rituximab doses (cumulative dose, 100-400 mg) owing to persistent active disease. Rituximab showed efficacy within 2 months in 13 of 15 (87%), stable at 1 year. No significant effect was observed on proptosis, lid fissure width, and eye motility. Conclusion: Low-dose rituximab showed sustained anti-inflammatory effect in most patients with active GO resistant to conventional treatment.

引用

页码：844 / 850

页数：7

共 21 条

[1] Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy [J].

Bartalena, L. ;

Krassas, G. E. ;

Wiersinga, W. ;

Marcocci, C. ;

Salvi, M. ;

Daumerie, C. ;

Bournaud, C. ;

Stahl, M. ;

Sassi, L. ;

Veronesi, G. ;

Azzolini, C. ;

Boboridis, K. G. ;

Mourits, M. P. ;

Soeters, M. R. ;

Baldeschi, L. ;

Nardi, M. ;

Curro, N. ;

Boschi, A. ;

Bernard, M. ;

von Arx, G. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (12) :4454-4463

[2] Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO [J].

Bartalena, Luigi ;

Baldeschi, Lelio ;

Dickinson, Alison ;

Eckstein, Anja ;

Kendall-Taylor, Pat ;

Marcocci, Claudio ;

Mourits, Maarten ;

Perros, Petros ;

Boboridis, Kostas ;

Boschi, Antonella ;

Curro, Nicola ;

Daumerie, Chantal ;

Kahaly, George J. ;

Krassas, Gerasimos E. ;

Lane, Carol M. ;

Lazarus, John H. ;

Marino, Michele ;

Nardi, Marco ;

Neoh, Christopher ;

Orgiazzi, Jacques ;

Pearce, Simon ;

Pinchera, Aldo ;

Pitz, Susanne ;

Salvi, Mario ;

Sivelli, Paolo ;

Stahl, Matthias ;

von Arx, Georg ;

Wiersinga, Wilmar M. .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (03) :273-285

[3] The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy [J].

Bartalena, Luigi ;

Baldeschi, Lelio ;

Boboridis, Kostas ;

Eckstein, Anja ;

Kahaly, George J. ;

Marcocci, Claudio ;

Perros, Petros ;

Salvi, Mario ;

Wiersinga, Wilmar M. .

EUROPEAN THYROID JOURNAL, 2016, 5 (01) :9-26

[4] Graves' Orbitopathy: Imperfect Treatments for a Rare Disease [J].

Bartalena, Luigi .

EUROPEAN THYROID JOURNAL, 2013, 2 (04) :259-269

[5] Orbital radiation for graves ophthalmopathy - A report by the American Academy of Ophthalmology [J].

Bradley, Elizabeth A. ;

Gower, Emily W. ;

Bradley, David J. ;

Meyer, Dale R. ;

Cahill, Kenneth V. ;

Custer, Philip L. ;

Holck, David E. ;

Woog, John J. .

OPHTHALMOLOGY, 2008, 115 (02) :398-409

[6] Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis [J].

Bredemeier, Markus ;

Campos, Guilherme G. ;

de Oliveira, Fernando K. .

CLINICAL RHEUMATOLOGY, 2015, 34 (10) :1801-1805

[7] Orbital radiotherapy for thyroid eye disease [J].

Dolman, Peter J. ;

Rath, Suryasnata .

CURRENT OPINION IN OPHTHALMOLOGY, 2012, 23 (05) :427-432

[8]

El Fassi D, 2006, THYROID, V16, P709

[9] Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study [J].

Erdei, Annamaria ;

Paragh, Gyorgy ;

Kovacs, Peter ;

Karanyi, Zsolt ;

Berenyi, Ervin ;

Galuska, Laszlo ;

Lenkey, Agota ;

Szabados, Lajos ;

Gyory, Ferenc ;

Ujhelyi, Bernadett ;

Berta, Andras ;

Boda, Judit ;

Berta, Eszter ;

Bodor, Miklos ;

Gazdag, Annamaria ;

Nagy, Endre V. .

AUTOIMMUNITY, 2014, 47 (08) :548-555

[10] Randomized, single blind trial of intravenous versus oral steroid monotherapy in graves' orbitopathy [J].

Kahaly, GJ ;

Pitz, S ;

Hommel, G ;

Dittmar, M .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (09) :5234-5240

← 1 2 3 →